

Your request

You requested the following:

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Apremilast
 - Bimekizumab
 - Brodalumab
 - Certolizumab
 - Deucravacitinib
 - Dimethyl fumarate
 - Etanercept - Enbrel
 - Etanercept Biosimilar
 - Guselkumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Ixekizumab
 - Risankizumab
 - Secukinumab
 - Tildrakizumab
 - Ustekinumab
2. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:
 - Ciclosporin
 - Methotrexate - any form and strength
 - Methotrexate injections 15mg and above

Our response

For questions 1 and 2, we do not hold information on the treatment drugs given to treat specific conditions on any digital system. To determine this, we would have to review every patient and pharmacy record. Therefore, to comply with your request, we have established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test.